Holen Sie sich die Stockscreener-App
11.94
8.94%
0.98
Handel nachbörslich:
11.96
0.02
+0.17%
Schlusskurs vom Vortag:
$10.96
Offen:
$11.78
24-Stunden-Volumen:
267.64K
Relative Volume:
0.82
Marktkapitalisierung:
$72.96M
Einnahmen:
$55.54M
Nettoeinkommen (Verlust:
$-180.40M
KGV:
-15.16
EPS:
-0.7877
Netto-Cashflow:
$-170.32M
1W Leistung:
+4.81%
1M Leistung:
+6.61%
6M Leistung:
-68.37%
1J Leistung:
-95.01%
1-Tages-Spanne:
$11.28
$12.45
1-Wochen-Bereich:
$9.961
$12.52
52-Wochen-Spanne:
$9.104
$309.60
Gossamer Bio Inc Stock (GOSS) Company Profile
Firmenname
Gossamer Bio Inc
Sektor
Branche
Telefon
(858) 684-1300
Adresse
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
11.94 | 65.57M | 55.54M | -180.40M | -170.32M | -0.7877 |
VRTX
Vertex Pharmaceuticals Inc
|
516.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
789.45 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
158.07 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
995.77 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
196.94 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2026-02-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2026-02-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-02-24 | Herabstufung | Wedbush | Outperform → Neutral |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-09-10 | Hochstufung | UBS | Neutral → Buy |
| 2025-07-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-05 | Fortgesetzt | Wedbush | Outperform |
| 2023-07-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-03-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | Eingeleitet | Guggenheim | Neutral |
| 2022-12-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-12-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-12-07 | Herabstufung | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | Eingeleitet | Goldman | Buy |
| 2022-09-21 | Eingeleitet | JP Morgan | Neutral |
| 2022-09-19 | Eingeleitet | Wedbush | Outperform |
| 2022-04-18 | Eingeleitet | Raymond James | Outperform |
| 2022-04-06 | Eingeleitet | UBS | Buy |
| 2022-01-10 | Hochstufung | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-09-21 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-30 | Eingeleitet | Berenberg | Buy |
| 2019-03-05 | Eingeleitet | Barclays | Overweight |
| 2019-03-05 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-05 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-05 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Gossamer Bio Inc Aktie (GOSS) Neueste Nachrichten
Gossamer Bio Inc (FRA:4GB0) Stock Price & 30 Year Financial Data - GuruFocus
Gossamer Bio (FRA:4GB0) PensionAndRetirementBenefit : €0.00 Mil (As of Jun. 2026) - GuruFocus
Gossamer Bio (FRA:4GB0) Net Issuance of Debt : €0.00 Mil (TTM As of Jun. 2026) - GuruFocus
Gossamer Bio Inc (FRA:4GB0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Form 8K Gossamer Bio Inc For: 11 September By Investing.com - Investing.com Nigeria
Gossamer Bio completes 1-for-80 reverse stock split By Investing.com - Investing.com Australia
Gossamer Bio Implements 1-for-80 Reverse Stock Split to Address Nasdaq Compliance - citybiz.co
Gossamer Bio Executes Reverse Stock Split and Share Reduction - TipRanks
Gossamer Bio completes 1-for-80 reverse stock split - investing.com
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split - Business Wire
GOSS: Static price chart | Gossamer Bio | US38341P1021 - marketscreener.com
Gossamer Bio: Dividend historical data and projections - marketscreener.com
Gossamer Bio: Performance & Quotes, GOSS Stock Price on Nasdaq Exchange - marketscreener.com
Gossamer Bio Stock (GOSS)Quote Nasdaq - marketscreener.com
Gossamer Bio To Carry Out 1-for-80 Reverse Stock Split On September 11th, 2026 - Moomoo
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - stocktwits.com
Gossamer Bio at Cantor Fitzgerald healthcare conference: filing path in focus - Investing.com Canada
Gossamer Bio Announces 1-for-80 Reverse Stock Split - tipranks.com
Gossamer Bio announces 1-for-80 reverse stock split, authorized shares cut to 50M - TradingView
Gossamer Bio Inc (GOSS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to earnings forward of Gossamer Bio, Inc. – NASDAQ:GOSS - TradingView
Biotech Gossamer Bio (NASDAQ: GOSS) markets $125M more in private securities - Stock Titan
Gossamer Bio to Present at Cantor Global Healthcare Conference - Yahoo Finance
Gossamer Bio seeks nod for 1.6B-share issuance | GOSS SEC FilingForm PRE 14A - stocktitan.net
Gossamer Bio Stock (GOSS) Opinions on Phase Advancement Catalysts - Moomoo
H.C. Wainwright reiterates Gossamer Bio stock rating on NDA progress By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Gossamer Bio stock rating on NDA progress - investing.com
Gossamer Bio (NASDAQ: GOSS) ties CFO’s 5.8M options to seralutinib FDA decision - Stock Titan
Gossamer Bio (NASDAQ: GOSS) ties CCO options to FDA drug decision - Stock Titan
GOSS 4-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS - Eastern Progress
Gossamer Bio (NASDAQ: GOSS) has 6% of its stock under D. E. Shaw’s reported influence - Stock Titan
Gossamer Bio Slides as $250M Financing Hinges on FDA Milestones - sahmcapital.com
Gossamer Bio (NASDAQ:GOSS) Funding Move Signals Biotech Shift - Kalkine Media
Gossamer Bio Secures Up To $250 Million To Fund Seralutinib Through Potential FDA Approval - pulse2.com
Latham Advises Gossamer Bio on Structured Private Placement - Latham & Watkins LLP
Latham Advises Gossamer Bio on Up to US$250 Million Structured Private Placement, Including US$150 Million of Committed Capital - Legal Desire
Gossamer Bio Slips as $250M Financing Hinges on FDA ApprovalGossamer Bio (NASDAQ:GOSS) - Benzinga
Gossamer Bio (GOSS) Raises $250M in Private Placement Amid Chall - GuruFocus
Gossamer Bio Secures Up to $250 Million Private Placement to Fund Seralutinib Through Potential FDA Approval - Yahoo Finance
Gossamer Bio Secures Up to $250M to Advance Seralutinib Toward FDA Approval - citybiz.co
$Gossamer Bio (GOSS.US)$ yessir 🦁 mode still early - Moomoo
Gossamer Bio (GOSS) Raises $250M in Private Placement Amid Challenging Valuation Landscape - GuruFocus
Gossamer Bio Agrees to Up to $250 Million Private Placement; Shares Rise Pre-Bell - marketscreener.com
Gossamer Bio secures up to $250m in milestone-based financing - Investing.com
$Gossamer Bio (GOSS.US)$ @traderslink_this_guy@TradersLink__ we never lacking 🤷♂️ 😉 - Moomoo
Gossamer Bio Lines Up Up To $250 Million Private Placement With Milestone-Triggered Warrants - TradingView
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval - Yahoo Finance
Gossamer Bio, Inc. announced that it expects to receive $250 million in funding - marketscreener.com
Revenue per share of Gossamer Bio, Inc. – HAM:4GB - TradingView
Gossamer Bio achieves exceptional financial eff... - Pluang
Gossamer Bio (GOSS) Stock Sees Fair Value Cut As Analysts Split On Seralutinib - Yahoo Finance
Finanzdaten der Gossamer Bio Inc-Aktie (GOSS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):